Deubiquitinating enzyme USP42 promotes breast cancer progression by inhibiting JNK/p38-mediated apoptosis
8.5
来源：
Nature
关键字：
mRNA
发布时间：
2025-10-21 23:51
摘要：
USP42, a deubiquitinating enzyme, plays a critical role in breast cancer progression by inhibiting apoptosis through the JNK/p38 signaling pathway. The study demonstrates that higher levels of USP42 correlate with advanced cancer stages and poor prognosis. Knockdown of USP42 in breast cancer cell lines led to reduced cell proliferation and increased apoptosis, indicating its potential as a therapeutic target. These findings underscore the importance of USP42 in breast cancer biology and highlight the need for further investigation into its mechanisms.
原文：
查看原文
价值分投票
评分标准
新闻价值分采用0-10分制，综合考虑新闻的真实性、重要性、时效性、影响力等多个维度。
评分越高，表示该新闻的价值越大，越值得关注。
价值维度分析
domain_focus
1.0分
business_impact
0.5分
scientific_rigor
1.5分
timeliness_innovation
1.5分
investment_perspective
2.5分
market_value_relevance
1.0分
team_institution_background
0.5分
technical_barrier_competition
0.5分
关键证据
USP42 expression was significantly higher in breast cancer tissues than in normal tissues.
USP42 knockdown resulted in decreased proliferation and increased apoptosis rates.
The study suggests USP42 as a potential therapeutic target in breast cancer treatment.
真实性检查
否
AI评分总结
USP42, a deubiquitinating enzyme, plays a critical role in breast cancer progression by inhibiting apoptosis through the JNK/p38 signaling pathway. The study demonstrates that higher levels of USP42 correlate with advanced cancer stages and poor prognosis. Knockdown of USP42 in breast cancer cell lines led to reduced cell proliferation and increased apoptosis, indicating its potential as a therapeutic target. These findings underscore the importance of USP42 in breast cancer biology and highlight the need for further investigation into its mechanisms.